Zacks Research Has Negative Outlook for CORT Q1 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for Corcept Therapeutics in a report issued on Wednesday, December 18th. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings per share of $0.27 for the quarter, down from their previous forecast of $0.29. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.34 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.53 EPS, Q2 2026 earnings at $0.55 EPS, Q3 2026 earnings at $0.71 EPS and FY2026 earnings at $2.41 EPS.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.14. The firm had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the company earned $0.28 EPS.

A number of other brokerages have also issued reports on CORT. Piper Sandler boosted their target price on Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday, September 18th. Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Corcept Therapeutics in a report on Thursday, October 31st. Truist Financial boosted their price target on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a research note on Monday, September 30th. Finally, StockNews.com lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $65.25.

Corcept Therapeutics Stock Performance

Shares of CORT stock opened at $51.15 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The firm has a market cap of $5.36 billion, a P/E ratio of 40.60 and a beta of 0.51. The firm’s 50 day moving average price is $53.71 and its 200-day moving average price is $41.78. Corcept Therapeutics has a one year low of $20.84 and a one year high of $62.22.

Institutional Investors Weigh In On Corcept Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Capital Performance Advisors LLP purchased a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at about $25,000. Kathleen S. Wright Associates Inc. purchased a new stake in Corcept Therapeutics in the third quarter valued at approximately $36,000. GAMMA Investing LLC boosted its holdings in shares of Corcept Therapeutics by 85.4% in the third quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 1,147 shares during the period. nVerses Capital LLC grew its position in shares of Corcept Therapeutics by 62.5% during the second quarter. nVerses Capital LLC now owns 3,900 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 1,500 shares during the last quarter. Finally, KBC Group NV increased its holdings in shares of Corcept Therapeutics by 21.3% in the 3rd quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 496 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 3,394 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $48.97, for a total value of $166,204.18. Following the sale, the insider now directly owns 5,796 shares of the company’s stock, valued at approximately $283,830.12. This represents a 36.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $59.46, for a total transaction of $130,812.00. The disclosure for this sale can be found here. Insiders have sold 26,811 shares of company stock valued at $1,341,360 in the last quarter. Corporate insiders own 20.50% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.